On April 1, 2026, TuHURA Biosciences, Inc. (NASDAQ:HURA) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside a corporate update. The company reported cash and cash equivalents of $3.6 million as of December 31, 2025, with an additional $7.5 million received in Q1 2026 from a registered direct offering. TuHURA's total shares outstanding were approximately 52.9 million. Research and development expenses for the year were $20.5 million, compared to $13.3 million in 2024. On a pro forma basis, which includes a full year of Kineta's research and development, these expenses were $22.1 million for 2025. General and administrative expenses also saw an increase, totaling $7.6 million for 2025, up from $3.9 million in 2024. The company reported net cash outflows from operating activities of $27.7 million for 2025, compared to $14.7 million in 2024. TuHURA's leadership expressed optimism about the future, highlighting the strategic strengthening of their clinical and drug development expertise with the addition of Dr. Craig Tendler as Chief Medical Officer. The company is advancing its clinical development pipeline, particularly with its VISTA inhibiting antibody, TBS-2025, and anticipates key milestones in its VISTA program this year. The ongoing IFx-2.0 Phase 3 study in front-line Merkel Cell Carcinoma (MCC) continues to enroll, with completion expected by mid-2027. TuHURA also initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0 as adjunctive therapy to Keytruda (pembrolizumab). The company raised gross proceeds of $21.2 million in registered direct offerings and private placements, demonstrating strong shareholder support. Overall, the financial results and strategic updates indicate a positive outlook for TuHURA, with significant advancements in their clinical programs and a solid financial foundation to support future growth.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.